Strength in numbers in the fight against cancer
Cooperation on cancer research at BiconY
Innovations in cancer research only happen when resources and knowledge are closely connected.
An adept alliance against cancer
As a SPRIND subsidiary and due to our close networking with Twyce GbmH, we have two partnerships in place that are essential to our goals. Expanding our network is a top priority for BiconY to further our vision of a world free from cancer. We are looking for pharmaceutical companies, universities and research institutions as well as other institutions and researchers who share our goal: to beat cancer.
The collaboration between Twyce, SPRIND and BiconY is more than just a business partnership: it represents an effective alliance that is helping to drive cancer research in Germany and around the world. The joint efforts of these three stakeholders are a living example of how networks and partnerships in the pharmaceutical sector can help to advance groundbreaking innovation. Join forces with us!
Side by side with strong partners in the fight against cancer
The relationship between SPRIND and BiconY is strategically important and is far more than just a parent-subsidiary relationship. SPRIND operates as a key player in supporting BiconY Therapeutics, particularly in legal matters and administrative corporate tasks. This ensures that BiconY is legally protected, leaving it to focus on its core area of expertise: developing innovative therapeutical approaches to treat solid tumours.
Close collaboration with Twyce
The close collaboration between Twyce and BiconY Therapeutics ensures that the latest advances in cancer immunotherapy can be implemented into clinical practice as rapidly as possible. Twyce was founded in 2023, but the research team has been active in the field of cancer immunotherapy and research for decades.
The partnership allows both companies to combine their forces, pool their resources and create synergies that help to improve cancer treatment in a lasting way. The combination of bispecific antibodies (bsAbs) and bispecific costimulators (BiCos) is opening up new possibilities in tumour therapy. Superior tumour specificity and double stimulation of T cells are expected to enable the development of more effective and safer therapy options for patients with solid tumours!
Networking for innovations in cancer research
We believe in the power of collaboration to achieve breakthrough advances in cancer immunotherapy. At BiconY Therapeutics, we are open to partnerships with organisations that share our vision and want to work together with us to revolutionise the treatment of solid tumours. Learn more about how to become part of our mission to produce innovative breakthroughs in cancer immunotherapy!
Research collaborations
We are looking for research institutions and universities we can work with to develop and validate innovative therapeutic approaches and novel treatment strategies. Together, we can pool our knowledge and resources to achieve new advances in cancer research. We are particularly looking for interdisciplinary involvement and not just partners within oncology!
Industry partnerships
We invite pharmaceutical and biotechnology companies interested in our BiCo technology to collaborate with us. We strive to create synergies and develop our technology for as many patients as possible.
FAQs on collaborating with BiconY
Find out more about our partnerships in cancer research:
How do BiconY and SPRIND work together?
SPRIND supports collaboration by securing patents and handling legal matters, so that BiconY can concentrate fully on developing its promising approaches to cancer research.
How do BiconY and Twyce work together?
BiconY Therapeutics works closely with Twyce GmbH to drive innovative research, particularly into the treatment of solid tumours. The core here is the “2 targets – 2 signals” concept developed by the renowned scientists Prof. Gundram Jung and Prof. Helmut Salih.
What is the purpose of this collaboration?
Cancer is still the number one cause of death. It’s time to change that! The companies involved form a network that aims to improve cancer therapy and develop innovative solutions to the challenges of treating solid tumours.
Is BiconY open to more collaborations in cancer research?
Of course! We are always looking for visionaries and heroes who are ready to roll up their sleeves, because no one can win the fight against cancer alone. Join us! We are looking for partnerships with research institutions, pharmaceutical companies and other interested institutions and organisations.
